Bortezomib plus dexamethasone for rituximab-resistant PLA2R(+) membranous nephropathy. Salhi S, Ribes D, Colombat M, Fortenfant F, et al. Kidney Int 2021;100:708-709.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Salhi S, Ribes D, Colombat M, Fortenfant F, et al. Bortezomib plus dexamethasone for rituximab-resistant PLA2R(+) membranous nephropathy. Kidney Int 2021;100:708-709.
PMID: 34420663